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Abstract  
The mesenchymal mode of cancer cell invasion characterized by active adhesion turnover and a 
polarized actin cytoskeleton, is critically regulated by the adaptor protein NEDD9/HEF1/Cas-L. 
While it is known that NEDD9 is subject to extensive phosphorylation modification, the molecules 
that determine NEDD9 phosphorylation to stimulate adhesion turnover and mesenchymal cell 
morphologies are currently unknown. Earlier studies have suggested that the serine/threonine 
phosphatase PP2A regulates interconversion between a low molecular mass NEDD9 phospho-form 
and higher molecular mass phosphoforms. However, previous studies have used chemical inhibitors 
to block PP2A activity. In the present study we therefore aimed to specifically inhibit PP2A activity 
via siRNA and dominant negative approaches to investigate the effect of PP2A on interconversion 
between 115kDa and 105kDa NEDD9 and determine the functional consequence of PP2A activity 
for NEDD9 function. Strikingly, we find that while the phosphatase inhibitor Calyculin A indeed 
abrogates detachment induced dephosphorylation of the 115kDa NEDD9 phospho-form, PP2A 
depletion does not inhibit 115kDa to 105kDa interconversion. Our data suggest instead that PP2A 
targets discrete NEDD9 phosphorylation modifications separate to the events that mediate 
interconversion between the two forms. Functionally, PP2A depletion increases NEDD9 mediated 
cell spreading and mutation of S369 in the serine-rich region of NEDD9 to aspartate mimics this 
effect. Importantly, mutation of S369 to alanine abrogates the ability of dominant negative PP2A to 
increase NEDD9-mediated cell spreading. Collectively, our data reveal that the tumour suppressor 
PP2A may act via S369 to regulated NEDD9-mediated cell spreading.  
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1. Introduction  
Individually invading cancer cells may switch between mesenchymal and amoeboid invasion 
modes, depending on the composition of the surrounding matrix [1, 2]. The mesenchymal invasion 
mode is characterized by a polarized actin cytoskeleton and depends on the regulated formation and 
disassembly of integrin-based adhesions to the surrounding extra-cellular matrix [3]. Recent 
advances have revealed that the adhesion docking protein NEDD9/HEF1/Cas-L is part of a 
signalling pathway that stimulates mesenchymal invasion and antagonizes amoeboid invasion [4]. 
Elevated expression of NEDD9 has been implicated as a metastasis promoter in a variety of tumour 
types [5]. NEDD9 contains multiple consensus serine, threonine and tyrosine phosphorylation 
motifs and extensive phosphorylation modification of the protein suggests that this is key to 
NEDD9 function [6]. Potential regulators of NEDD9 phosphorylation status are the PP2A 
phosphatases [7]. This enzyme family displays tumour suppressor activity [8] and regulates a 
variety of cellular signalling pathways; however the consequence of PP2A activity for NEDD9 
adhesion-mediated functions has not been reported. 
 
NEDD9 is an adhesion docking protein that forms part of a signalling hub at integrin-mediated 
adhesion sites [6]. Lacking enzymatic activity, NEDD9 regulates the formation of signalling 
complexes via its protein-protein interaction domains: a Src Homology 3 (SH3) domain; followed 
by an SH2-binding domain that contains at least 17 tyrosine residues that can be phosphorylated in 
vivo (Phosphosite database [9]); a serine-rich region encompassing 27 serine residues and; a highly-
conserved C-terminal domain [10]. Phosphorylation of serines, threonines and tyrosines in the 
NEDD9 sequence modulate NEDD9 interaction with down-stream signalling partners and thus 
regulate NEDD9’s signalling function.  
 
NEDD9 is frequently reported as a doublet of ~105kDa and 115kDa molecular mass by western 
blot and more recently a third intermediary phosphoform was reported [11]. The relative expression 
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of the NEDD9 phospho-forms differs between cell  lines and tissues [12]. 105kDa NEDD9 is 
phosphorylated on multiple tyrosine residues and serine residues, while the 115kDa form is 
additionally phosphorylated on threonine [13-15]. 105kDa NEDD9 interconverts to 115kDa 
NEDD9 in response to integrin-mediated adhesion [16, 17]. Following treatments that disrupt either 
the actin cytoskeleton or adhesion, 115kDa NEDD9 collapses to form 105kDa NEDD9. This can be 
abrogated by treatment with Okadaic acid and Calyculin A [16-18]. Based on the data obtained 
using Okadiac acid and Calyculin A – two natural products with PP2A inhibitory activity - a model 
has been proposed whereby cell detachment leads to PP2A activation, which is then proposed to 
catalyze the interconversion from 115kDa to 105kDa NEDD9 [7]. Moreover, a recent study 
demonstrated that mutation of S369 in the NEDD9 serine-rich region specifically abrogated 
Okadaic acid-stimulated interconversion between 105kDa and 115kDa NEDD9 [11]. This suggests 
that PP2A may target NEDD9 S369. However, both Okadaic acid and Calyculin A inhibit 
phosphatases in addition to PP2A [17, 19]. Thus to specifically demonstrate the role of PP2A in the 
interconversion between 115kDa and 105kDa NEDD9, approaches that directly target PP2A are 
required.  
 
The PP2A holoenzyme exists as a tri-molecular complex of regulatory (B), catalytic (C) and 
scaffolding (A) subunits and multiple isoforms of each subunit provides alternative substrate 
specificities and sub-cellular distributions. An extensive body of work now provides significant 
support for the notion that PP2A phosphatases have tumour suppressor activity and it is emerging 
that one of the functions of this protein may be to suppress cell migration. Inhibition of PP2A 
activity via mutation in a regulatory B sub-unit stimulated rapid and extensive cell spreading and 
the switch to a polarized cytoskeleton characteristic of the mesenchymal morphology [20], while 
siRNA-mediated targeting of the PP2A catalytic sub-unit enhanced cell migration [21]. Notably, 
NEDD9 overexpression also promotes cell spreading [16, 22-24] and leads to a mesenchymal 
pattern of actin rearrangement [22]. This switch to mesenchymal invasion is characterized by a 
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polarized actin cytoskeleton in which a short mesh work of actin filaments is localized to the 
protruding edge and behind the leading edge discrete actin filament populations are arrayed 
perpendicular (dorsal arcs) and parallel (transverse arcs) to the leading edge [3]. Thus inhibition of 
PP2A activity and increased NEDD9 expression stimulate similar cellular phenotypes, suggesting 
the possibility that PP2A may suppress NEDD9-mediated spreading and inhibit the switch to a 
mesenchymal phenotype. 
 
The aim of the present study was to compare the effects of Calyculin A treatment versus PP2A 
knockdown on the interconversion between 115kDa and 105kDa NEDD9 and investigate the 
functional consequence of PP2A activity for NEDD9 function. Our data suggest that PP2A does not 
regulate the interconversion between 115kDa and 105kDa NEDD9 but instead targets discrete 
NEDD9 phosphorylation modifications separate to those that mediate interconversion. We show 
that PP2A suppresses NEDD9 mediated cell spreading and demonstrate a requirement for NEDD9 
S369 in this process. 
 
2. Materials and Methods 
2.1 Antibodies and Reagents 
Monoclonal antibodies to NEDD9 (clone 2G9) were from ImmuQuest (Cleveland, UK), 
monoclonal anti-tubulin and purified mouse IgG were purchased from Sigma (Missouri, USA) and 
phospho-specific anti-PP2A-C Y307 monoclonal antibodies were from Epitomics (California, 
USA).  Antibodies against PP2A-C (clone 1D6) were from Upstate (California, USA).  Secondary 
HRP-conjugated anti-mouse and anti-rabbit antibodies were from Amersham (New Jersey, USA) 
and Biorad (California, USA) and 4’,6-diamidino-2-phenylindole (DAPI) was from Sigma.  Cy3-
tagged anti-phalloidin was purchased from Sigma and reconstituted in methanol. Calyculin 
(Chemicon, California, USA) was resuspended in DMSO and MG132 was purchased from 
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Calbiochem (CA, USA). SiGENOME pooled siRNAs directed against the PP2A subunit and non-
targeting siRNA pool #1 were purchased from Dharmacon (Colorado, USA) and reconstituted in 
RNAse free water.   
 
2.2 Creation of GST-fusion peptides and expression plasmids with site-specific mutations. 
Expression plasmids encoding NEDD9 fused with GFP have been previously described ([16]. The 
GST.SRR expression construct was prepared by inserting cDNA coding for NEDD9 amino acids 
351 – 653 into EcoR1-XhoI cloning sites of the pET-41a(+) vector (Novagen). Site specific 
mutation of Serine 369 to either alanine (S369A) or aspartate (S369D) was achieved using a PCR-
based mutagenesis as previously described [25] using GFP.NEDD9 as the template. Primers for 
mutagenesis were as follows: S369A (forward: 
5’GGATGGGATCAACCGATTGGCTTTCTCCAGTACAGGCAGCAC3’, reverse: 
5’GTGCTGCCTGTACTGGAGAAAGCCAATCGGTTGATCCCATCC3’) and S369D (forward: 
5’GGATGGGATCAACCGATTGGATTTCTCCAGTACAGGCAGCAC3’, reverse 
5’GTGCTGCCTGTACTGGAGAAATCCAATCGGTTGATCCCATCC3’). Details of the 
dominant negative PP2A catalytic sub-unit (PP2Ac-L199P) have been previously reported [26]. 
 
2.3 Cell culture  
MCF-7 cells were maintained in Dulbecco’s Modified Eagles Medium (DMEM, Invitrogen, 
Victoria, Australia) supplemented with 10% FBS (Invitrogen) at 37
o
C with 5% CO2.  For all 
experiments, cells were cultured in phenol-red free DMEM plus 10% charcoal treated FBS 
supplemented with 10nM estradiol for at least 7 days prior to the experiment. Development of the 
tetracycline-regulatable MCF-7 line was previously described [22].  NEDD9 expression was 
induced by culturing cells in the absence of tetracycline for 16-24 hours.  
 
2.4 RNA interference  
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For siRNA knock-down cells (7 x 10
5
) were plated in 35mm tissue culture dishes and incubated 
overnight. Transfections were performed using RNAiMax (Invitrogen) according to manufacturer’s 
instructions. Briefly, RNAiMaxor and 3pmoles of siRNA were incubated to form complexes in 
Opti-Mem for 20 min and cells then incubated with RNAiMaxor-RNA solution for 6 hours.  
Transfections were repeated in the same cells 24 hours later to achieve robust knock-down and cells 
were collected for analysis 72 hours post initial transfection. 
 
2.5 Phosphorylation kinetics 
Cell quiescence was achieved as described previously [7]. Briefly, 24 hours post final siRNA 
transfection, culture media was changed to serum-free DMEM with 0.1% heat inactivated bovine 
serum albumin (hiBSA).  Cells were then rinsed with PBS and detached by incubation with 3mM 
EDTA at 37°C for 15 min.  Following resuspension in hiBSA, cells were held in suspension by 
plating into bacterial Petri dishes for the required time.  The zero time point represents cells 
following detachment with 3mM EDTA prior to resuspension in hiBSA. For all time points floating 
cells were collected, washed in PBS and extracted in PTY lysis buffer as normal.  
 
2.6 Co-immunoprecipitation and GST pull-downs. 
For co-immunoprecipitation analysis, cells were washed twice with ice-cold PBS and incubated in 
lysis buffer (10mM Tris-HCl pH 7.5, 5mM EDTA pH 8.0, 50mM sodium fluoride, 10mM 
dithiothreitol, 2mM sodium orthovanadate, 1mM phenylmethylsulfonyl fluoride, 1% nonidet P-40 
(NP-40), 0.05% SDS, 0.25% sodium deoxycholate, 10ug/ml leupeptin, 10ug/ml aprotinin) at 4
o
C 
for 30 min.  Lysates were briefly centrifuged and supernatants collected. Protein A-Sepharose 
(Sigma) was prepared by swelling beads in 10mM HEPES buffer, pH 7.2 for 30 min on ice then 
washing in PBS and resuspending beads in an equal volume of lysis buffer.  Lysates were pre-
cleared with protein A-sepharose for 1 hr at 4
o
C then collected by centrifugation (10,000 x g) and 
resulting supernatants incubated with anti-NEDD9, PP2A-C or isotype-matched, mouse IgG 
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antibodies at 4
o
C for 2 hrs.  After the addition of protein A-Sepharose slurry, incubations were 
continued overnight at 4
o
C.  The resin was collected and washed five times with 0.5% NP-40 in 
phosphate-buffered saline then proteins dissociated from the beads by boiling. 
 
For GST pull-downs, bacterial cells were washed with ice-cold PBS and incubated in lysis buffer 
(50mM HEPES pH 7.4, 150mM NaCl, 2mM EDTA, 2mM sodium fluoride, 2% nonidet P-40 (NP-
40), 0.5% sodium deoxycholate, 0.36mM sodium orthovanadate, Protease inhibitor cocktail 
(Sigma)) at 4
o
C for 10 min.  Lysates were briefly centrifuged and supernatants collected. The lysate 
was pre-cleared of endogenous GSTs and non-specifically binding proteins present by incubating 
with Glutathione Sepharose 4B (GE Healthcare) three times for 30 min. Pre-cleared lysate (250 l) 
was incubated with 20 l of 1 mg/ml GSH-GST.SRR beads or GSH-recombinant GST (control) 
beads at 4°C for 1 hr. Beads were transferred to a Micro Bio-spin column (BioRad) and washed six 
times with TBS and four times with 20mM Tris, pH 7.4. Proteins bound to the beads were eluted in 
1x SDS sample loading buffer at 85° C. 
 
 
2.7 SDS-PAGE and western blotting 
Where indicated, cells were pre-treated with Calyculin A for 4 hours. As the addition of Calyculin 
A stimulated cell rounding, in all Calyculin treated experiments floating cells were collected and 
extracted for analysis. Protein extractions, equalisation and immunoblotting were performed as 
previously described [27].  Proteins were separated by electrophoresis in 6% acrylamide SDS-
polyacrylamide gels to detect NEDD9 and 12% to detect PP2A-C. 
 
2.8 Imaging and image analysis 
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Cells grown on coverslips were fixed in 4% paraformaldehyde for 10 min, permeabilised in wash 
solution (0.2% triton X-100 in 0.5% BSA) for 5 min then incubated with Cy3 labelled phalloidin  
diluted 1/1000 in wash solution for 1 hour at room temperature.  Cells were then counterstained 
with DAPI (diluted 1/10000) for 15 min and coverslips mounted onto microscope slides with 
FluorSave (Calbiochem, San-Diego, USA).  Fluorescent imaging was performed using an Olympus 
IX81 inverted microscope (Olympus, Pennsylvannia, USA) and images captured by using an 
ORCA ERG cooled CCD camera (Hamamatsu/SDR Clinical Technology).  Final micrograph 
images and gray level adjustments were prepared in Adobe Photoshop. Cell measurements were 
carried out using Metamorph V6.3 software and final data analysis in X-cel. Densitometric analysis 
of protein detection on western blots was achieved using ImageJ 1.34S software (NIH, USA). 
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3. Results 
3.1 PP2A does not regulate the interconversion of 115kDa to 105kDa NEDD9 
Detachment from the sub-stratum and treatments that disassemble the actin cytoskeleton all lead to 
the loss of 115kDa NEDD9 [16-18] and blockade of this effect with either Calyculin A or Okadaic 
acid has led to the suggestion this is mediated by PP2A activity [7]. That is, PP2A has been 
suggested to mediate detachment-induced dephosphorylation of 115kDa NEDD9 to produce 
105kDa NEDD9. Consistent with previous observations, treatment with either Calyculin A (Figure 
1A) or Okadaic acid (data not shown) robustly inhibited suspension-induced accumulation of 
105kDa NEDD9. Both 105kDa and 115kDa NEDD9 appear to have reduced electrophoretic 
mobility in the presence of Calyculin, suggesting that there may be multiple phospho-intermediates 
of each form. Moreover, the total levels of NEDD9 are decreased in the presence of calyculin 
agreeing with earlier data reporting targeting of hyper-phosphorylated NEDD9 by the proteasome 
[7]. These data are in accord with earlier reports indicating that Calyculin A and Okadaic acid both 
block suspension-induced interconversion from 115kDa NEDD9 to 105kDa NEDD9.  
 
We next used siRNA targeting the catalytic sub-unit of PP2A (PP2A-C) to establish the role of 
PP2A in the detachment-induced interconversion of 115kDa and 105kDa NEDD9. Knock-down of 
PP2A routinely achieved >50% reduction in PP2A-C protein (Figure 1B) and kinetic analysis of 
NEDD9 phosphoforms in suspended cells following PP2A-C knockdown was performed. 
Comparison of the effects of Calyculin A treatment and PP2A depletion revealed striking 
differences in NEDD9 regulation (compare Figure 1A and 1B). There is little evidence of 115kDa 
NEDD9 accumulation in suspended cells following PP2A knock-down (Figure 1B). Moreover, the 
PP2A-C knock-down suspended cells retained prominent expression of 105kDa NEDD9 (Figure 
1B), in direct contrast to effects seen with Calyculin A treatment. Analysis of the change in 
phospho-forms over the 60 minute time course revealed depletion of 115kDa NEDD9 and no 
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change in the levels of 105kDa NEDD9 in suspended cells following PP2A depletion (Figure 1C 
and 1D). The differences observed between the effects of Calyculin A and PP2A siRNA therefore 
suggest that unlike Calyculin A treatment, PP2A depletion does not block the suspension-induced 
conversion of 115kDa to 105kDa NEDD9. Given that NEDD9 is a highly phosphorylated protein 
that contains multiple serine residues, PP2A may therefore target phosphorylated residues of 
NEDD9 that are distinct from those that mediate interconversion between 105kDa and 115kDa 
NEDD9. 
 
3.2  NEDD9 and PP2A interact via the NEDD9 SRR domain. 
To further investigate the potential interaction between NEDD9 and PP2A we next determined 
whether NEDD9 interacts with PP2A in vivo, by performing co-immunoprecipitations from cell 
lysates. This revealed that PP2A-C co-immunoprecipitates with anti-NEDD9 antibodies and 
conversely, that NEDD9 co-immunoprecipitates with anti-PP2A-C antibodies (Figure 2A). Notably, 
both NEDD9 phospho-forms were observed to co-immunoprecipitate with PP2A and the ratio of 
co-immunoprecipitating 105kDa to 115kDa NEDD9 (that is, greater levels of 105kDa NEDD9) is 
similar to the ratio of endogenous NEDD9 in the whole cell lysate (Figure 2A(ii)). For additional 
confirmation that NEDD9 forms a complex with PP2A we performed GST-pull-downs. As it is not 
possible to express full length NEDD9 in bacteria, we instead used the NEDD9 serine-rich region 
(SRR) that has previously been suggested to have the same tertiary structure as the SRR domain of 
the highly related molecule p130Cas [28]. The high level of serine residues encompassed by the 
SRR suggested that PP2A may interact with NEDD9 via this domain, therefore we prepared 
expression constructs encoding the SRR domain fused to GST (Figure 2B and 2C). Importantly, 
pull-downs with the GST.NEDD9.SRR from cell lysates successfully isolated the catalytic sub-unit 
of PP2A (Figure 2D), therefore demonstrating that PP2A interacts with the SRR domain of 
NEDD9.  
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3.3 PP2A regulates NEDD9-mediated cell spreading. 
It is known that elevated NEDD9 expression stimulates cell spreading [22, 24, 29] and the adoption 
of a polarized actin cytoskeleton that characterizes the mesenchymal morphology [3, 22]. 
Therefore, we next measured the effect of PP2A knock-down on NEDD9-mediated cell spreading 
and morphologies, following NEDD9 induction as previously described [22]. First, we examined 
the effect of PP2A-C knock-down on total NEDD9 phospho-forms in the adherent cells that had 
been induced to express NEDD9 (Figure 3A and 3B). In the adherent cells, little difference was 
observed in NEDD9 phospho-forms subsequent to PP2A-C knock-down (Figure 3B). By 
comparison, Calyculin A treatment of adherent MCF-7 cells causes a striking loss of 105kDa 
NEDD9 and a smear of high molecular weight isoforms (Figure 3C) similar to the pattern seen in 
suspended cells treated with Calyculin A (Figure 1A). Remarkably, knock-down of PP2A-C 
combined with induced NEDD9 expression stimulated significantly increased cell spreading when 
compared with the induction of NEDD9 alone (Figure 3D and E). Examination of cell 
morphologies following PP2A-C knock-down additionally revealed significantly increased 
crescent-shaped cells, typified by polarized distribution of actin filaments including an actin 
filament meshwork at the leading edge, transverse arcs parallel to the leading edge and dorsal stress 
fibres perpendicular to the leading edge (Figure 3F). Thus, these data suggest that PP2A reduces 
NEDD9-mediated effects on cell spreading and mesenchymal cell morphology. 
 
3.4 Increased cell spreading following PP2A depletion and elevated NEDD9 requires S369. 
Mutation of NEDD9 serine 369 to alanine abrogates the formation of higher molecular weight 
forms of NEDD9 in response to Okadaic acid treatment [11]. Agreeing with this, we find that the 
S369A mutation also blocks formation of 115kDa induced by Calyculin A treatment (Figure 4B). 
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To next determine whether constitutive phosphorylation of S369 rescues the formation of 115kDa 
NEDD9, we prepared a phospho-mimetic construct in which S369 was mutated to aspartate 
(S369D). However, no doublet of S369D mutant protein was observed, even after longer exposure 
times of the autoradiograph (Figure 4B). Similarly, although treatment with Calyculin A stimulated 
increased 115kDa GFP.NEDD9 expression relative to the 105kDa form, S369D remained as a 
single lower molecular mass band (Figure 4B). The lack of an S369D doublet does not appear to be 
due to proteasomal degradation of the upper 115kDa form, as neither treatment with MG132 alone 
nor in combination with Calyculin A stimulated a prominent doublet of this mutant protein (Figure 
4B). Thus these data suggest that the phospho-mimetic mutation cannot rescue 115kDa NEDD9 
formation. 
 
Importantly, both S369A and S369D were detected at focal adhesions, as seen for the wild-type 
NEDD9 GFP fusion protein (GFP.NEDD9) (Figure 4C). To determine the consequence of the S369 
point mutations for cell spreading, we measured cell area following transfection with each construct 
compared to empty vector (GFP) and wild-type NEDD9 (GFP.NEDD9) controls. This revealed that 
the S369A mutant protein increased the cell area to the same extent as seen for cells expressing 
wild-type GFP.NEDD9 (Figure 4C). In contrast, the S369D mutant construct stimulated a striking 
further increase in cell area, resulting in cells with significantly larger area than either GFP.NEDD9 
or S369A transfectants (Figure 4C). Together, these data suggest that although phosphorylation of 
S369 is not absolutely required for NEDD-mediated cell spreading, it is sufficient to stimulate 
increased cell spreading. 
 
To investigate the relationship between S369 and PP2A activity, we next employed a PP2A 
dominant negative expression construct, which allowed us to examine combinations of PP2A 
inhibition together with NEDD9 expression constructs (Figure 5A-C). Quantification of cell areas 
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revealed that PP2A.DN alone promoted increased MCF-7 cell spreading (Figure 5A and C). 
Agreeing with the earlier data showing that elevated NEDD9 expression and PP2A siRNA 
simulated significantly increased cell area (Figure 3E), combined expression of PP2A.DN and 
GFP.NEDD9 resulted in cell areas that were significantly larger than cells transfected with either 
PP2A.DN or GFP.NEDD9 alone (Figure 5C). Critically, this effect was lost when S369A was co-
expressed with PP2A.DN, as there was no difference in area between cells expressing PP2A.DN 
and S369A either alone or in combination (Figure 5C). This suggests that the increased cell area 
resulting from combined exogenous NEDD9 expression and decreased PP2A activity may be 
mediated by S369. 
 
Discussion 
The PP2A serine/threonine phosphatases regulate a variety of cellular signalling pathways and 
disruption of these pathways via loss of PP2A activity results in cellular transformation [30]. In the 
present study, we show that NEDD9 function is regulated by the PP2A class of tumour suppressor 
phosphatases. Identification of NEDD9 as part of this tumour suppressor signalling network 
underscores the important role that deregulated NEDD9 function plays in cancer progression. 
 
This study has investigated the previously proposed model that PP2A catalyses detachment-induced 
dephosphorylation of 115kDa NEDD9 to produce the 105kDa NEDD9 [7]. However, using siRNA-
mediated knock-down of PP2A to allow detection of the specific PP2A mediated effects, we have 
shown that PP2A does not catalyse detachment-induced dephosphorylation of 115kDa NEDD9. 
Indeed, loss of 115kDa NEDD9 appeared to be more rapid subsequent to PP2A knock-down. 
Instead, our data suggest that PP2A is likely to regulate phosphorylation modifications of NEDD9 
that are discrete from the events required to interconvert 105kDa and 115kDa NEDD9. 
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Functionally, we have shown that PP2A suppresses NEDD9-mediated adhesion dynamics that 
underlie cell spreading and reduces the NEDD9-mediated switch to mesenchymal morphologies. 
We have further established that NEDD9 and PP2A interact in vivo via the NEDD9 SRR domain. 
We propose that increased levels of NEDD9 – either following NEDD9 induction, or in invasive 
cancers with increased NEDD9 expression [5] - may exceed the PP2A molecules available for 
interaction, thus leading to increased cell spreading and mesenchymal morphology. The 
combination of elevated NEDD9 and decreased PP2A via either siRNA-mediated knock-down or 
expression of dominant negative PP2A may therefore further shift this balance, resulting in 
additional increases in NEDD9-mediated spreading. Given that inhibition of PP2A activity alone 
promotes cell spreading (Figure 5C) it was possible that PP2A depletion and NEDD9 may stimulate 
cell spreading via parallel pathways. However, we show that mutation of NEDD9 S369 to alanine 
abrogates dominant negative PP2A-induced increases in cell spreading. Therefore, this reveals that 
NEDD9 and PP2A functionally interact to regulate cell spreading. Moreover the finding that the 
S369D phospho-mimetic construct mimics the effects of PP2A knock-down, suggests that the 
phosphorylation of this residue is critical to NEDD9 function in adhesion dynamics that lead to cell 
spreading. Notably, as expression of the S369A mutant protein alone stimulates spreading 
equivalent to wild-type GFP.NEDD9, there are likely to be other components of the NEDD9 
sequence in addition to S369 that regulate cell spreading. 
 
Targeting of PP2A function via dominant negative approaches [20, 31] and siRNA mediated knock-
down (present study) leads to increased cell spreading.  In addition to the interaction with NEDD9 
demonstrated in the present study, PP2A interacts with other adhesion regulators including beta 
integrins [32, 33], the integrin-adhesion associated protein paxillin [34] and the NEDD9-related 
molecule p130Cas [35]. Each of these proteins contribute to the regulation of adhesion dynamics 
[36] and collectively these data therefore point to a role for PP2A in regulating the integrin 
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adhesion dynamics that determine mesenchymal invasion. Moreover PP2A appears to collaborate 
with NEDD9 to determine the extent of cell spreading and adoption of mesenchymal morphology. 
A role for PP2A as a suppressor of cell invasion is particularly interesting, given its role as a 
tumour suppressor. The switch to an invasive, metastatic phenotype is one of the key features of 
tumour progression and an increasing number of studies have identified NEDD9 as an important 
metastasis promoter in a range of tumour types [5]. Moreover, NEDD9-mediated invasion is 
stimulated following inactivation of another tumour suppressor molecule, LKB1 [37]. Together our 
data suggest that PP2A may serve as a brake on NEDD9 mediated functions in normal cells and 
that following cell transformation and PP2A loss, NEDD9 promotion of mesenchymal invasion 
may be switched on.  
 
The emerging importance of NEDD9 as a regulator of mesenchymal invasion means that this 
protein is an attractive target for novel anti-cancer therapies. However, as NEDD9 is a scaffold that 
mediates protein-protein interaction, direct targeting of the NEDD9 protein for therapeutic purpose 
may be technically challenging. An alternative approach is to target enzymes such as PP2A that 
regulate NEDD9. The PP2A activator molecule, FTY270/fingolimod, has shown great promise for 
the treatment of malignancies [38, 39]. Activating mutations of the oncogene c-KIT inhibited PP2A 
and reversal of this with the PP2A activator FTY270 led to the conclusion that PP2A inhibition is 
essential for c-KIT mediated tumorigenesis [39]. Thus it may be relevant that a recent study 
established that NEDD9 is also a c-KIT target [40]. In future studies it will be of significant interest 
to determine whether PP2A activation may also have efficacy against NEDD9-mediated invasion in 
vivo. 
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Legends 
Figure 1. PP2A does not regulate 105kDa to 115kDa NEDD9 interconversion. A. Western blot 
detection of NEDD9 expression in lysates from attached MCF-7 cells (control), cells placed in 
suspension (sus.) or pre-incubated with 10nM calyculin for 4 hours and then placed in suspension. 
The histogram shows representative data of the ratio of 115kDa/105kDa NEDD9 for each 
condition, relative to the control sample. B. MCF-7 cells transfected with control siRNA (control) 
or siRNA targeting PP2A-C, were placed in suspension (sus.) and incubated for the indicated times 
(mins). The histogram underneath shows the ratio of 115kDa/105kDa NEDD9 with time, expressed 
relative to the level at ‘0’. The heavy signal of the tubulin loading control for the NEDD9 blot 
reflects the quantity of total protein (75 g) required in order to visualize NEDD9; tubulin was not 
used to normalize protein expression levels. C and D. 115kDa NEDD9 and 105kDa expression, 
respectively, in suspension cultures relative to the zero time point. Black points show data for cells 
treated with control siRNA and white points represent data for cells treated with PP2A-C siRNA. 
All experiments were repeated in triplicate on separate days and the average of three experiments is 
shown. Error bars show the SEM. Statistical analysis was performed using two-way ANOVA with 
Bonferroni post-tests, *p<0.001, NS = not significant. 
 
Figure 2. NEDD9 SRR interacts with PP2A. A. Proteins were immunoprecipitated (IP) with the 
indicated antibodies (control= isotype matched antibody control) from extracts of cells induced to 
express NEDD9. Western blots were probed with the indicated antibodies (WB) and whole cell 
lysates (WCL) included as controls. (i) demonstrates PP2A-C co-immunoprecipitating with anti-
NEDD9 antibody complexes and (ii) shows NEDD9 co-immunoprecipitating with anti-PP2A-C 
complexes. *105kD NEDD9, **115kD NEDD9. B. Schematic representation of NEDD9 protein 
domains in full length NEDD9 (834 amino acids) (SH3: Src Homology 3, SH2BD: Src Homology 2 
Binding Domain, SRR: Serine Rich Region, CT: C-terminus) and the GST.SRR fusion protein used 
in GST pull-down experiments. C. Coomassie stained gel showing the induction of GST.SRR. 
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Protein extracts were prepared from bacteria transformed with the GST.SRR expression construct 
under control conditions (control) or following induction of the fusion protein (induced). D. 
Western blot detection of PP2A-C in whole cell lysates (WCL) and following pull-down with 
glutathione beads coupled to GST control and with the GST.SRR fusion protein. 
 
Figure 3. PP2A-C knockdown promotes NEDD9-mediated cell spreading. A. Western blot 
confirming induction of NEDD9. B. NEDD9 and PP2A-C in protein extracts from the inducible 
NEDD9 expression cells transfected with siRNA targeting the PP2A catalytic sub-unit (PP2A-C) or 
control siRNA.  Blots were probed with tubulin to confirm equal protein loading. Top histogram 
shows representative data of the ratio of 115kDa NEDD9 to 105kDa NEDD9 under the indicated 
conditions. The lower histogram shows the average % PP2A-C protein remaining following siRNA 
targeting, from 3 independent experiments. C. Western blot of lysates from adherent MCF-7 cells 
under control conditions or treated with Calyculin A. Duplicate samples are shown. D. Cells 
induced to express NEDD9 and transfected with control or PP2A-C targeted siRNA, fixed and 
probed with fluorescently-tagged phalloidin to detect filamentous actin. Arrows indicate typical 
crescent-shaped cells. 50m scale bar. E. Area of cells induced to express NEDD9 and transfected 
with control or PP2A-C targeted siRNA. Data represent the mean of 3 independent experiments 
(>45 cells measured per experiment). F. Higher magnification image (60x objective) of typical 
crescent-shaped cell from a culture expressing elevated NEDD9 and transfected with PP2A-C 
targeted siRNA. Fluorescently-tagged phalloidin detects the meshwork of short actin filaments in 
the leading edge (M), the transverse arcs (TA) arrayed parallel to the leading edge and the dorsal 
stress fibres (D) at right angles to the leading edge. 10m scale bar. Histogram indicates the 
percentage of crescent-shaped cells. Data represent the average of 3 independent experiments. Error 
bars represent the S.E.M. *p<0.05, Students t-test. 
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Figure 4. Mutation of NEDD9 S369 recapitulates PP2A knock-down effects. A. Schematic 
representation of NEDD9 protein sequence indicating position of S369. B. Western blot analysis of 
MCF-7 cells transfected with the indicated expression constructs. Exogenous GFP-fused NEDD9 
protein phospho-forms are indicated. Transfected cells were grown under control conditions, in the 
presence of Calyculin A or MG132 alone and in combination. Two different exposure times (short 
and longer) of autoradiographs are shown to aid in the identification of GFP.NEDD9 phospho-
forms. Note that only the lanes with wild-type GFP.NEDD9 display the high molecular mass 
115kDa NEDD9 phospho-form. C. Images of MCF-7 cells transfected with the indicated expression 
constructs. Arrows point to GFP fusion proteins localized to focal adhesions. Scale bar 20 μm. D. 
Average area of GFP positive cells. Data are calculated from triplicate repeats on separate 
occasions. Values were compared using one-way ANOVA with Tukey's Multiple Comparison test, 
*p<0.05, NS=not significant. 
 
Figure 5. Mutation of NEDD9 S369 abrogates spreading induced by dominant negative PP2A.  A. 
Images of MCF-7 cells transfected with the indicated expression constructs. Cells in the bottom row 
were co-transfected with plasmid encoding dominant negative PP2A (PP2A.DN). Scale bar 20 μm. 
B. Western blot analysis of MCF-7 cells transfected with the indicated expression constructs. Cells 
were co-transfected with GFP expression constructs and either empty vector control (-) or 
PP2A.DN (+) as indicated. C. Average area of GFP positive cells. Data are calculated from 
triplicate repeats on separate occasions (~50 cells for each condition per experiment). Values were 
compared using one-way ANOVA with Tukey's Multiple Comparison test, ***p<0.001, NS=not 
significant. 
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